Contraindications
Cross-source consensus on Contraindications from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Other
Highlighted claims
- Absolute contraindications to ACEi/ARB/ARNI and MRA therapy were rare. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- For SGLT2 inhibitors, eGFR below 20 mL/min/1.73 m² was the most important contraindication. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- Second- or third-degree atrioventricular block was the most common beta-blocker contraindication. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- Renal concerns may have been applied more broadly than strict guideline contraindications required. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- The article suggests renal impairment concerns may have contributed to avoidable underuse, particularly in CKD stage 3. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study